DBV Technologies S.A. (DBVT) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Entera Bio (ENTX) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 30.6% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -3.6% for ENTX. Entera Bio is the larger company by market cap ($575.5 million vs $566.8 million), about 1.0 times the size, while DBV Technologies S.A. is growing revenue faster (+35.8% vs -76.8%).
DBV Technologies S.A. converts more of its revenue into profit, with a net margin of -2607.3% versus -27235.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | ENTX |
|---|---|---|
| Share price | $9.02 | $3.31 |
| Market cap | $566.82M | $575.53M |
| 1-day change | -4.25% | +0.76% |
| YTD return | -52.95% | +70.36% |
| 1-year return | -34.40% | +30.63% |
| 5-year return | +50.33% | -3.64% |
| EPS (TTM) | $-3.00 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $42.00K |
| Revenue growth (YoY) | +35.77% | -76.80% |
| Net income (latest FY) | $-146.95M | $-11.44M |
| Gross margin | — | 0.00% |
| Operating margin | -2609.23% | -27450.00% |
| Net margin | -2607.29% | -27235.71% |
| 52-week high | $26.19 | $4.20 |
| 52-week low | $8.63 | $0.91 |
| Distance from 52-week high | -65.55% | -21.31% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +305.10% | +195.01% |
| Average volume | 352.88K | 438.35K |
| Shares outstanding | 62.84M | 174.14M |
| Employees | 179 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed DBVT by 65.0 percentage points over the past year.
- DBV Technologies S.A. is more profitable, keeping -2607.3 cents of every revenue dollar as net income versus -27235.7 cents for Entera Bio.
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -76.80%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
DBVT vs ENTX FAQ
Which is bigger, DBV Technologies S.A. or Entera Bio?
Entera Bio (ENTX) is larger, with a market capitalization of $575.53M compared with $566.82M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or ENTX?
ENTX returned +30.63% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.